The Patented Medicine Prices Review Board’s 2023-24 Departmental results report: At a glance

A departmental results report provides an account of actual accomplishments against plans, priorities and expected results set out in the associated Departmental Plan.

• Vision, mission, raison d’être and operating context
• Minister’s mandate letter

Read the full Departmental results report

---

Key priorities

The Patented Medicine Prices Review Board (PMPRB)’s top priorities for 2023-24 were as follows:

• Implement new pricing framework and begin evaluating its impact
• Support the Government’s high-level priorities for the future of pharmaceutical management in Canada

These priorities were refocused over the course of the fiscal year to better reflect the PMPRB’s current operational context, as expressed in the PMPRB’s 2024-25 Departmental Plan.

---

Highlights

In 2023-24, total actual spending (including internal services) for the PMPRB was $14,044,145 and the total full-time equivalent staff (including internal services) was 82. For complete information on the PMPRB’s total spending and human resources, read the Spending and human resources section of the full report.

The following provides a summary of the department’s achievements in 2023-24 according to its approved Departmental Results Framework. A Departmental Results Framework consists of a department’s core responsibilities, the results it plans to achieve, and the performance indicators that measure progress toward these results.

Core responsibility 1: Regulate Patented Medicine Prices

Actual spending: $10,223,542

Actual human resources: 58

Departmental results achieved

• Affordable patented drug prices^{Footnote 1}
  
  The PMPRB launched a consultations process to inform new draft Guidelines in 2023-24, releasing a Scoping Paper in November 2023 and hosting Policy Roundtable sessions in December to seek feedback from interested groups. Draft Guidelines will give PMPRB Staff direction in conducting price reviews under the amended Patented Medicine Regulations.
  
  In absence of Guidelines, the PMPRB conducted price reviews under Interim Guidance. This guidance was amended September 2023 to respond to the extended period of Guidelines development.
  
  As part of its reporting mandate, the PMPRB published four analytic reports and five posters in addition to authoring two journal articles over the course of the fiscal year. These studies offer a range of information on pharmaceutical pricing and sales in Canada and internationally.

More information about Regulate Patented Medicine Prices can be found in the ‘Results – what we achieved’ section of the full departmental results report.